A Phase I Single Ascending Dose Study of RO7126209 in Healthy Japanese Subjects

Chugai Pharmaceutical Co., Ltd.0 个研究点目标入组 32 人开始时间: 2021年7月7日最近更新: 2023年1月30日

适应症

试验速览

暂无简介。

•Written informed consent.
•Healthy Japanese man who is 20 to 40 years of age at the time of informed consent.
•Individuals who are judged to be healthy based on their medical, history surgical history, or physical examination.
•Body mass index (weight [kg]/[height [m]2) of 18.5 to 25.0 kg/m2 at screening.
•Individuals who have agreed to abstinence or to use contraception methods and to refrain from sperm donation during the study treatment period and for a certain period after administration of the investigational drug.

•Individuals with cardiovascular, renal, hepatic, gastrointestinal, immunological, neurological, endocrine, metabolic, cerebrovascular, or bronchopulmonary diseases and individuals with a history of these diseases and disorder kidney, liver, or cardiorespiratory function.
•Individuals affected by hypersensitivity to biological products or excipients in pharmaceutical products.
•Subjects who participated in any clinical trial within 4 months before administration of the investigational product and who received the investigational product (including placebo).
•Individuals who have received or have taken prescription drugs within 1 month before administration of the investigational product.

safety Observation

未报告次要终点

发起方